Drug Trial Radar · NCT07648030
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Oct 28, 2027
Study completion May 17, 2030
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots. Many people with PV need regular phlebotomy, which is a procedure to remove blood, to help keep their hematocrit level under control. Hematocrit is the proportion of red blood cells in the blood. The main aim of this study is to evaluate whether rusfertide helps Japanese participants with PV keep their hematocrit under control and avoid the need for phlebotomy. All participants in this study will receive rusfertide. This study is open-label, which means both the participants and the study team will know what treatment is being given. Participants will be followed for up to about 244 weeks, including a screening period, a 52-week initial treatment period, a long-term extension period, and a 4-week safety follow-up period.
Conditions
- Polycythemia Vera
Interventions
RusfertideDrug
Rusfertide injections administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Response Starting at Week 20 through Week 32Time frame: Week 20, up to Week 32
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Miyazaki Hospital
Miyazaki, Japan · Recruiting
Nagoya Medical Center
Nagoya, Aichi-ken, Japan · Recruiting
Gunma University Hospital
Maebashi, Gunma, Japan · Not yet recruiting
Mie University Hospital
Tsu, Mie-ken, Japan · Recruiting
University of Osaka Hospital
Suita, Osaka, Japan · Recruiting
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan · Recruiting
Tokyo Metropilitan Bokutoh Hospital
Sumida-ku, Tokyo, Japan · Recruiting
University of Yamanashi Hospital
Chūō, Yamanashi, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.